NovoSeven
Biological
Novo Nordisk Inc
Total Payments
$1.4M
Transactions
505
Doctors
238
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $123,406 | 108 | 53 |
| 2023 | $138,976 | 163 | 95 |
| 2022 | $132,351 | 124 | 77 |
| 2021 | $985,913 | 110 | 60 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $904,469 | 2 | 65.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $232,409 | 73 | 16.8% |
| Consulting Fee | $157,965 | 80 | 11.4% |
| Travel and Lodging | $65,532 | 85 | 4.7% |
| Food and Beverage | $19,885 | 253 | 1.4% |
| Education | $387.24 | 12 | 0.0% |
Payments by Type
Research
$904,469
2 transactions
General
$476,178
503 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| FVIIa for Acute hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial | Novo Nordisk Inc | $720,000 | 0 |
| FVIIa for Acute | Novo Nordisk AS | $184,469 | 0 |
Top Doctors Receiving Payments for NovoSeven
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cincinnati, OH | $909,986 | 7 |
| , MD | Pediatrics | Nashville, TN | $45,524 | 35 |
| , MD | Pediatric Hematology-Oncology | Charleston, SC | $40,205 | 33 |
| , M.D | Pediatrics | Charlotte, NC | $25,071 | 20 |
| , M.D | Pediatrics | Seattle, WA | $24,891 | 7 |
| , MD | Hematology | Iowa City, IA | $23,056 | 7 |
| , APRN | Pediatrics | Nashville, TN | $22,505 | 22 |
| , M.D | Pediatrics | Las Vegas, NV | $21,639 | 10 |
| , MD | Hematology & Oncology | Chapel Hill, NC | $20,160 | 6 |
| , M.D | Pediatrics | Orlando, FL | $17,758 | 8 |
| , MD | Pediatric Hematology-Oncology | Redlands, CA | $16,812 | 15 |
| , MD | Hematology & Oncology | Louisville, KY | $15,946 | 10 |
| , MD | Pediatric Hematology-Oncology | Madison, MS | $15,692 | 11 |
| , M.D | Pediatrics | Peoria, IL | $15,569 | 10 |
| , MD | Pediatric Hematology-Oncology | Ann Arbor, MI | $13,840 | 4 |
| , M.D | Internal Medicine | Chattanooga, TN | $13,287 | 6 |
| Craig Kessler | Hematology & Oncology | Washington, DC | $9,995 | 5 |
| , M.D | Pediatrics | Chicago, IL | $9,973 | 9 |
| , M.D | Hematology | Los Angeles, CA | $9,876 | 6 |
| , M.D | Pediatric Hematology-Oncology | San Juan, PR | $9,350 | 4 |
| , M.D | Adult Medicine | Franklin, WI | $9,245 | 3 |
| , MD | Pediatrics | Detroit, MI | $7,560 | 2 |
| , MD | Pediatrics | Detroit, MI | $7,560 | 2 |
| , NP | Family | Los Angeles, CA | $4,522 | 5 |
| Richard Lemons | Pediatric Hematology-Oncology | Salt Lake City, UT | $3,987 | 2 |
Ad
Manufacturing Companies
- Novo Nordisk Inc $1.1M
- Novo Nordisk AS $232,907
- Novo Nordisk Health Care AG $76,935
Product Information
- Type Biological
- Total Payments $1.4M
- Total Doctors 238
- Transactions 505
About NovoSeven
NovoSeven is a biological associated with $1.4M in payments to 238 healthcare providers, recorded across 505 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk Inc.
Payment data is available from 2021 to 2024. In 2024, $123,406 was paid across 108 transactions to 53 doctors.
The most common payment nature for NovoSeven is "Unspecified" ($904,469, 65.5% of total).
NovoSeven is associated with 2 research studies, including "FVIIa for Acute hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial" ($720,000).